This is not a “normal” stock. There is no point thinking about this stock’s price movements as one would with other stocks. No point in deciphering this stock’s chart either. All such effort is waste of energy and time. Only post approval and moving off OTC can this stock be evaluated in normal terms like any other stock. Till then it can’t be called a pig or a swan. It is what it is, in a world by itself.
Yes, hoping the future SOC of all cancer tumors can hold 25 cents a share. Taking a much needed break from this complete BS of a company and stock. I hope they take the recent settlement and give themselves a much deserved bonus.
Market Data 
Markets 
AI
